Effect of renin-angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy.

Shohei Moriyama Michinari HiedaMegumi KisanukiShotaro KawanoTaku YokoyamaMitsuhiro FukataHitoshi KusabaToru MaruyamaEishi BabaKoichi AkashiHaruhisa Fukuda

Published in: Open heart (2023)

RASIs for hypertension do not benefit clinical outcomes during cancer therapy with VSP inhibitors. In addition, RASIs and calcium channel blockers have comparable clinical efficacy as first-line antihypertensive.

Keyphrases

cancer therapy
blood pressure
drug delivery
vascular endothelial growth factor
hypertensive patients
angiotensin converting enzyme
mesenchymal stem cells
newly diagnosed
bone marrow